13F filer · CIK 1103804 ↗
Viking Global
You are looking at Q2 2023. See the latest, Q2 2026 →
Reported value
$24.43B
+15% on the quarter before
Positions
86
21 new · 16 sold out
Top 10
37.3%
of the value
Est. gain
+$1.48B
on stocks held all quarter
Est. return
+9.4%
on those stocks since Q1 2023
Positions as of Jun 30, 2023, from Viking Global's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q1 2023. Striped tiles are options.
Largest buys
Since Q1 2023, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Danaher Corporation~$1.02BNew · 0.0% → 4.2%+4,256,761 shares
- Philip Morris Intl Inc~$884.0MNew · 0.0% → 3.6%+9,055,492 shares
- Workday~$541.3MAdded · 0.6% → 2.8%+2,396,172 shares
- Cbre Group Inc~$369.5MNew · 0.0% → 1.5%+4,578,096 shares
- Everest Re Group Ltd~$354.9MNew · 0.0% → 1.5%+1,038,182 shares
- Arista Networks~$330.0MNew · 0.0% → 1.4%+2,036,587 shares
- Netflix~$277.9MNew · 0.0% → 1.1%+630,865 shares
- Fortive Corp~$258.1MAdded · 2.0% → 3.0%+3,451,701 shares
- International Flavors&Fragra~$219.5MAdded · 0.4% → 1.2%+2,757,286 shares
- DoorDash~$206.4MNew · 0.0% → 0.8%+2,700,350 shares
Largest sells
Since Q1 2023, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Mckesson Corp~$1.15BCut · 5.4% → 0.9%−2,682,937 shares
- Chubb Limited~$480.6MCut · 3.2% → 0.8%−2,495,798 shares
- Amazon~$420.7MCut · 3.7% → 2.3%−3,226,907 shares
- Elevance Health Inc~$329.6MCut · 4.6% → 2.6%−741,855 shares
- Fortinet~$316.4MCut · 3.7% → 2.4%−4,186,097 shares
- Csx Corp~$315.4MCut · 3.1% → 1.8%−9,250,168 shares
- Lululemon Athletica Inc~$266.6MCut · 3.2% → 1.8%−704,289 shares
- Meta~$182.3MCut · 3.2% → 3.0%−635,366 shares
- Rogers Comms B~$172.9MCut · 1.2% → 0.3%−3,790,300 shares
- General Electric Co~$161.9MCut · 3.9% → 3.2%−1,474,056 shares
Holdings
As of Jun 30, 2023. Changes are in shares against Mar 31, 2023, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visa Inc.COM CL A · shares +8.8% · price +5.3% | 6.9% | $1.70B | +$78.9M | ||||||||
| Danaher CorporationCOM · shares New | 4.2% | $1.02B | — | ||||||||
| Api Group CorpCOM STK · shares +0.3% · price +21.3% | 3.8% | $932.3M | +$163.0M | ||||||||
| Philip Morris Intl IncCOM · shares New | 3.6% | $884.0M | — | ||||||||
| Unitedhealth Group IncCOM · shares −15% · price +1.7% | 3.5% | $862.4M | +$14.4M | ||||||||
| General Electric CoCOM NEW · shares −17% · price +14.9% | 3.2% | $784.1M | +$101.7M | ||||||||
| Roivant Sciences LtdSHS · shares −15% · price +36.6% | 3.1% | $758.4M | +$203.1M | ||||||||
| MetaCL A · shares −20% · price +35.4% | 3.0% | $744.6M | +$194.7M | ||||||||
| Fortive CorpCOM · shares +54% · price +9.7% | 3.0% | $732.6M | +$41.9M | ||||||||
| WorkdayCL A · shares +373% · price +9.4% | 2.8% | $686.4M | +$12.4M | ||||||||
| Hdfc Bank LtdSPONSORED ADS · shares +12% · price +4.5% | 2.7% | $649.1M | +$25.1M | ||||||||
| Elevance Health IncCOM · shares −34% · price −3.4% | 2.6% | $627.6M | −$21.9M | ||||||||
| Sherwin Williams CoCOM · shares +1.0% · price +18.1% | 2.5% | $604.0M | +$91.8M | ||||||||
| FortinetCOM · shares −35% · price +13.7% | 2.4% | $581.2M | +$70.2M | ||||||||
| AmazonCOM · shares −42% · price +26.2% | 2.3% | $573.8M | +$119.1M | ||||||||
| IntuitCOM · shares −14% · price +2.8% | 2.0% | $482.6M | +$13.0M | ||||||||
| Bridgebio Pharma IncCOM · shares 0% · price +3.7% | 1.9% | $457.9M | +$16.5M | ||||||||
| Lululemon Athletica IncCOM · shares −37% · price +3.9% | 1.8% | $450.3M | +$17.0M | ||||||||
| Csx CorpCOM · shares −42% · price +13.9% | 1.8% | $436.7M | +$53.3M | ||||||||
| Thermo Fisher Scientific IncCOM · shares −2.8% · price −9.5% | 1.8% | $434.7M | −$45.5M | ||||||||
| CadenceCOM · shares +43% · price +11.6% | 1.7% | $410.5M | +$29.9M | ||||||||
| MicrosoftCOM · shares +15% · price +18.1% | 1.7% | $409.3M | +$54.7M | ||||||||
| MastercardCL A · shares +27% · price +8.2% | 1.6% | $398.3M | +$23.8M | ||||||||
| Ameriprise Finl IncCOM · shares +19% · price +8.4% | 1.5% | $373.4M | +$24.1M | ||||||||
| Cbre Group IncCL A · shares New | 1.5% | $369.5M | — | ||||||||
| Total · 86 positions | 100% | $24.43B | +$1.48B |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q1 2023 to Q2 2023: 64 stocks held throughout, up $1.48B (+9.4%).
- Roivant Sciences Ltd+$203.1M+37%
- Meta+$194.7M+35%
- Api Group Corp+$163.0M+21%
- Amazon+$119.1M+26%
- General Electric Co+$101.7M+15%
- Biomarin Pharmaceutical Inc−$22.9M−11%
- Amylyx Pharmaceuticals Inc−$23.0M−26%
- Thermo Fisher Scientific Inc−$45.5M−9%
- Royalty Pharma Plc−$52.1M−15%
- Adaptive Biotechnologies Cor−$63.6M−24%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | $35.08B−2% | SEC ↗ |
| Q1 2026 | May 15, 2026 | $35.75B−5% | SEC ↗ |
| Q4 2025 | Feb 17, 2026 | $37.68B−2% | SEC ↗ |
| Q3 2025 | Nov 14, 2025 | $38.50B+11% | SEC ↗ |
| Q2 2025 | Aug 14, 2025 | $34.59B+10% | SEC ↗ |
| Q1 2025 | May 15, 2025 | $31.48B+2% | SEC ↗ |
| Q4 2024 | Feb 14, 2025 | $30.90B+13% | SEC ↗ |
| Q3 2024 | Nov 14, 2024 | $27.44B+5% | SEC ↗ |
| Q2 2024 | Aug 14, 2024 | $26.02B−3% | SEC ↗ |
| Q1 2024 | May 15, 2024 | $26.86B−2% | SEC ↗ |
| Q4 2023 | Feb 14, 2024 | $27.30B+11% | SEC ↗ |
| Q3 2023 | Nov 14, 2023 | $24.64B+1% | SEC ↗ |
| Q2 2023 | Aug 14, 2023 | $24.43B+15% | SEC ↗ |
| Q1 2023 | May 15, 2023 | $21.31B+7% | SEC ↗ |
| Q4 2022 | Feb 14, 2023 | $19.98B−8% | SEC ↗ |
| Q3 2022 | Nov 14, 2022 | $21.66B−1% | SEC ↗ |
| Q2 2022 | Aug 15, 2022 | $21.86B−12% | SEC ↗ |
| Q1 2022 | May 16, 2022 | $24.74B−29% | SEC ↗ |
| Q4 2021 | May 16, 2022 (amended) | $34.71B−5% | SEC ↗ |
| Q3 2021 | May 16, 2022 (amended) | $36.46B+11% | SEC ↗ |
| Q2 2021 | Aug 16, 2021 | $32.98B−2% | SEC ↗ |
| Q1 2021 | May 17, 2021 | $33.58B−8% | SEC ↗ |
| Q4 2020 | Feb 16, 2021 | $36.37B+31% | SEC ↗ |
| Q3 2020 | Nov 16, 2020 | $27.68B+20% | SEC ↗ |
| Q2 2020 | Aug 7, 2020 | $23.14B+20% | SEC ↗ |
| Q1 2020 | May 13, 2020 | $19.21B−10% | SEC ↗ |
| Q4 2019 | Feb 13, 2020 | $21.35B+11% | SEC ↗ |
| Q3 2019 | Nov 13, 2019 | $19.20B−14% | SEC ↗ |
| Q2 2019 | Aug 14, 2019 | $22.29B+28% | SEC ↗ |
| Q1 2019 | May 15, 2019 | $17.44B−1% | SEC ↗ |
| Q4 2018 | Feb 14, 2019 | $17.57B−3% | SEC ↗ |
| Q3 2018 | Nov 14, 2018 | $18.06B+3% | SEC ↗ |
| Q2 2018 | Aug 14, 2018 | $17.47B+5% | SEC ↗ |
| Q1 2018 | May 15, 2018 | $16.61B+2% | SEC ↗ |
| Q4 2017 | Feb 14, 2018 | $16.26B+5% | SEC ↗ |
| Q3 2017 | Nov 14, 2017 | $15.44B+4% | SEC ↗ |
| Q2 2017 | Aug 14, 2017 | $14.85B−34% | SEC ↗ |
| Q1 2017 | May 15, 2017 | $22.64B+3% | SEC ↗ |
| Q4 2016 | Feb 14, 2017 | $22.01B−5% | SEC ↗ |
| Q3 2016 | Nov 14, 2016 | $23.18B−2% | SEC ↗ |
| Q2 2016 | Aug 15, 2016 | $23.54B+4% | SEC ↗ |
| Q1 2016 | May 16, 2016 | $22.72B | SEC ↗ |